Lyra Therapeutics Pursues ENLIGHTEN 2 Trial for LYR-210

TipRanks16:33 ET

Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know

Yahoo FinanceJan 9 12:00 ET

Michael Altman and Konstantin Poukalov Resign From Lyra Therapeutics Board

Dow JonesDec 13, 2024 17:28 ET

Lyra Health Welcomes Jennifer Schulz as Chief Executive Officer

BusinesswireDec 5, 2024 10:05 ET

Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

BusinesswireDec 3, 2024 08:00 ET

Lyra Therapeutics: Hold Rating Due to Uncertainty in ENLIGHTEN-2 Trial Outcomes

TipRanksNov 14, 2024 06:16 ET · Ratings